Manasa Gunturu, MD
Neurology · Jackson, MSNPI 1174937148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $369 and has fallen 66.9% since, to $122 in 2025. That places this record below the midpoint for neurology clinicians in MS, where the typical reported total is $1,546.
Across 61 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$204
- Amgen$133
- EMD Serono, Inc.$129
- UCB, Inc.$90
- Sanofi$84
- Catalyst Pharmaceuticals, Inc.$83
- plus $399 from 14 others
Across 2 payments — averaging $41,337 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$83K
What the payments were for
- Speaking & faculty fees$343%
- Food & beverage$1,08897%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $204 |
| Amgen(2 entities) | 3 | $133 |
| EMD Serono, Inc. | 8 | $129 |
| UCB, Inc. | 5 | $90 |
| Sanofi | 4 | $84 |
| Catalyst Pharmaceuticals, Inc. | 2 | $83 |
| Neurocrine Biosciences, Inc. | 4 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| Avanir Pharmaceuticals, Inc. | 4 | $50 |
| Kyowa Kirin, Inc. | 3 | $41 |
| Acorda Therapeutics, Inc | 2 | $34 |
| Upsher-smith Laboratories LLC | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| AstraZeneca | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| GE HealthCare | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| SK Life Science, Inc. | 1 | $12 |
How this compares
$1,123 in reported general payments places this provider in the 40th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 15 | $307 |
Paid to pharmacies, not to this prescriber.
Other neurology in Jackson
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Rajesh SharmaJackson$152K
- Patrick WeldonJackson$85K
- Riichi OtaJackson$53K
- Mitchell MyersJackson$43K
- Tiffany ScarffJackson$29K
- Derek LetortJackson$25K
- Shreyas GangadharaJackson$20K
- Juebin HuangJackson$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.